Latest Cancer vaccine Stories
Vaccine scientists say their "Holy Grail" is to stimulate immunity that lasts for a lifetime. Live viral vaccines such as the smallpox or yellow fever vaccines provide immune protection that lasts several decades, but despite their success, scientists have remained in the dark as to how they induce such long lasting immunity.Scientists at the Emory Vaccine Center have designed tiny nanoparticles that resemble viruses in size and immunological composition and that induce lifelong immunity in...
NEW YORK, Feb. 23, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs. Developed by Dr. Hideho Okada, Associate Professor of Neurological Surgery and his...
ORLANDO, Fla., Feb. 18, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 - 19, 2011. Three leading medical specialty societies co-sponsor the symposium, including the American Society of...
SEATTLE, Feb. 17, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the 2011 Genitourinary Cancers Symposium annual meeting in Orlando, Florida. "Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies," abstract #139. Reception and General Poster Session B: Prostate Cancer (A33) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011."Characterization of...
BETHESDA, Md., Feb. 14, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chair of the Board of Directors, Ms. Linda Powers, will give a corporate presentation at the 13th Annual Biotechnology Industry Organization's BIO CEO & Investor Conference being held February 14th, 2011 at 2:00 pm in the Conrad Room of the Waldorf Astoria Hotel in New York City. Ms. Powers will provide a corporate and clinical update, including an update on NWBT's...
TORONTO, Feb. 3, 2011 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Manufacturing Services Agreement with Oncovir, Inc., a specialty pharma company based in Washington DC, dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Dalton Pharma Services will provide API manufacturing...
WORCESTER, Mass., Feb. 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer...
BLUE BELL, Pa., Jan. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial (WIN Trial) to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device. This open-label, multi-center clinical trial being run by the University of Southampton is evaluating a DNA vaccine to treat...
In an effort to increase access to Lucanix, IRCC has been chosen as the first U.S. research center by NovaRx to provide an "Expanded Access" trial of Lucanix to a limited number of qualified research participants.San Diego, CA (PRWEB) January 26, 2011 Innovative Research Center of California (IRCC) is an independent, dedicated research facility that specializes in new treatments for Oncology and Medicine. IRCC's team of investigators and research coordinators have decades of...
WORCESTER, Mass., Jan. 25, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that it has amended the Clinical Study Agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (www.hjf.org) in regard to the on-going Phase II clinical study of Antigen's AE37 novel...
